Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Profit After Tax (2017 - 2025)

Arcus Biosciences has reported Profit After Tax over the past 9 years, most recently at -$106.0 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 12.77% year-over-year to -$106.0 million; the TTM value through Dec 2025 reached -$353.0 million, down 24.73%, while the annual FY2025 figure was -$353.0 million, 24.73% down from the prior year.
  • Profit After Tax for Q4 2025 was -$106.0 million at Arcus Biosciences, up from -$135.0 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $279.5 million in Q4 2021 and troughed at -$135.0 million in Q3 2025.
  • A 5-year average of -$60.9 million and a median of -$76.0 million in 2021 define the central range for Profit After Tax.
  • On a YoY basis, Profit After Tax climbed as much as 639.1% in 2021 and fell as far as 4379.64% in 2021.
  • Year by year, Profit After Tax stood at $279.5 million in 2021, then crashed by 123.97% to -$67.0 million in 2022, then dropped by 20.9% to -$81.0 million in 2023, then decreased by 16.05% to -$94.0 million in 2024, then dropped by 12.77% to -$106.0 million in 2025.
  • Business Quant data shows Profit After Tax for RCUS at -$106.0 million in Q4 2025, -$135.0 million in Q3 2025, and -$112.0 million in Q1 2025.